Skip to main content
SpringerLink
Log in

First-Line Chemotherapy in Advanced Pancreatic Cancer

  • Chapter
Pancreatic Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 177))

Abstract

This chapter focuses on first-line therapy in inoperable pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 209.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997.) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    Google Scholar 

  3. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C (2004) Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 16:265–274

    Article  PubMed  Google Scholar 

  4. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, et al. (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Gastrointestinal Cancers Symposium abstr 77

    Google Scholar 

  5. Kondo S, Ueno H, Okusaka T, Ikeda M, Morizane C, Najima M (2006) Gemcitabine monotherapy versus chemoradiotherapy using 5-FU in patients with locally advanced pancreatic cancer. 2006 Gastrointestinal Cancers Symposium, ASCO Abstr 137

    Google Scholar 

  6. Huguet F, André T, Hammel P, et al. (2006) Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locally-advanced (LA) pancreatic cancer patients: retrospective analysis of 181 patients enrolled in prospective phases II and III GERCOR studies. J Clin Oncol 23:4095

    Google Scholar 

  7. Chauffert B, Mornex F, Bonnetain F, Triboulet JP, Bouche O, Rougier P, Bosset JF, Aparicio T, Masskouri F, Bedenne L (2006) Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. ASCO Annual Meeting Proceedings Part I (June 20 Supplement) 4008. J Clin Oncol 24:18S

    Article  Google Scholar 

  8. Lionetto R, Pugliese V, Bruzzi P, Rosso R (1995) No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 31A:882–887

    Article  PubMed  CAS  Google Scholar 

  9. Taylor I (1993) Should further studies of chemotherapy be carried out in pancreatic cancer? Eur J Cancer 29:1076–1078

    Article  Google Scholar 

  10. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

    PubMed  CAS  Google Scholar 

  11. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885

    Article  PubMed  CAS  Google Scholar 

  12. Poplin E, Levy DE, Berlin J, Rothenberg L, Cella D, Mitchell E, Alberts S, Benson A 3rd (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24:4004

    Google Scholar 

  13. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270–3275

    Article  PubMed  CAS  Google Scholar 

  14. Moore MJ, Hamm J, Dancey J, et al. (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302

    Article  PubMed  CAS  Google Scholar 

  15. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783

    Article  PubMed  CAS  Google Scholar 

  16. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167

    Article  PubMed  CAS  Google Scholar 

  17. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA; Marimastat Pancreatic Cancer Study Group (2001) Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3477–3455

    Google Scholar 

  18. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645

    Article  PubMed  CAS  Google Scholar 

  19. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438

    Article  PubMed  Google Scholar 

  20. Louvet C, Labianca R, Hammel P, et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516

    Article  PubMed  CAS  Google Scholar 

  21. Banu E, Oudard S, Banu A, et al. (2005) Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC). J Clin Oncol (meeting abstracts) 23:4101

    Google Scholar 

  22. Pelzer U, Stieler J, Roll L, Stauch M, Opitz B, Scholten T, Hahnfeld S, Dörken B, Riess H, Oettle H (2006) A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT—CONKO 004). ASCO Annual Meeting Proceedings Part I. J Clinic Oncol 24:18S [June 20 Suppl]:4110

    Google Scholar 

  23. Cunningham D, Chau I, Stocken DD, Davies C, Dunn JA, Valle J, Smith D, Steward WP, Harper P, Neoptolemos J (2005) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 3 [Suppl 4]:12

    Google Scholar 

  24. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernhard J, Dietrich D, Scheithauer W (2005) Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 23(16S)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany

    Uwe Pelzer

Authors
  1. Uwe Pelzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pelzer, U. (2008). First-Line Chemotherapy in Advanced Pancreatic Cancer. In: Pancreatic Cancer. Recent Results in Cancer Research, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71279-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-71279-4_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-71266-4

  • Online ISBN: 978-3-540-71279-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation